Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838542 | 1.00 | CTSS (0.49) | CTSSCTSKCTSBAAK1RIPK1 | |
| SCHEMBL4704028 | 1.00 | CTSS (0.49) | CTSSCTSKCTSBAAK1RIPK1 | |
| SCHEMBL29676847 | 1.00 | CTSS (0.49) | CTSSCTSKCTSBAAK1RIPK1 | |
| SCHEMBL38666123 | 0.90 | CTSK (0.47) | CTSSCTSKCTSBAAK1 | |
| SCHEMBL29423245 | 0.90 | CTSK (0.47) | CTSSCTSKCTSBAAK1 | |
| SCHEMBL16410211 | 0.90 | CTSK (0.47) | CTSSCTSKCTSBAAK1 | |
| SCHEMBL28069901 | 0.90 | CTSK (0.47) | CTSSCTSKCTSBAAK1 | |
| SCHEMBL16410292 | 0.88 | CTSS (0.48) | CTSSCTSKCTSBAAK1 | |
| SCHEMBL22805508 | 0.87 | CTSS (0.50) | CTSSCTSKCTSBAAK1 | |
| SCHEMBL22690656 | 0.87 | CTSK (0.50) | CTSSCTSKCTSBAAK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270200-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2025-08-28 | — | — | US | disclosed |
| WO-2023205475-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1581510-A4 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2006-08-30 | — | — | EP | disclosed |
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-7045551-B2 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1581510-A2 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6784182-B2 | AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004047743-A2 | 1-ARYL-2-HYDROXYETHYL AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | CTSS 51/4885CTSK 100/4885CTSB 141/4885 |
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | CTSS 107/4885CTSK 133/4885CTSB 179/4885 |
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | CTSS 131/4885CTSK 220/4885CTSB 210/4885 |
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | KCNQ3, KCNQ2, KCNQ4 | CTSS 1946/4885CTSK 1918/4885CTSB 3131/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | CTSS 201/4885CTSK 286/4885CTSB 285/4885 |
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | CTSS 201/4885CTSK 286/4885CTSB 285/4885 |
| US-20250270200-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | CTSS 184/4885CTSK 1207/4885CTSB 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.